

Amrubicin

Catalog No: tcsc2836



Available Sizes

Size: 1mg

Size: 5mg



Specifications

CAS No:

110267-81-7

Formula:

$C_{25}H_{25}NO_9$

Pathway:

Cell Cycle/DNA Damage

Target:

Topoisomerase

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 30 mg/mL (62.05 mM)

Alternative Names:

SM-5887; AMR

Observed Molecular Weight:

483.47


Product Description

Amrubicin is a DNA **topoisomerase II** inhibitor, used for the research of cancer.

IC₅₀ & Target: Topoisomerase II^[1]

In Vitro: Amrubicin is a DNA topoisomerase II inhibitor. Amrubicin (2.5 µg/mL) shows radio-enhancement effects on human lung adenocarcinoma A549 cells^[1]. Amrubicin suppresses the LX-1, A549, A431, and BT-474 cell lines, with IC₅₀s of 1.1 ± 0.2, 2.4 ± 0.8, 0.61 ± 0.10 and 3.0 ± 0.3 µg/mL, respectively^[2]. Amrubicin inhibits the cell cycle profile of U937 cells with an IC₅₀ of 5.6 µM. Amrubicin (20 µM) also induces apoptosis in U937 cells, activates caspase-3/7 and reduces the mitochondrial membrane potential (Δψ_m)^[3].

In Vivo: Amrubicin (25 mg/kg, i.v.) exhibits significant antitumor activities against both SCLC tumors, Lu-24 and Lu-134, with T/C-values (comparing the mean tumor growth rates of the treated group with those of the control group for each day that the tumors are measured) at day 14 of 17% and 9%, respectively. Amrubicin (25 mg/kg, i.v.) in combination with cisplatin and irinotecan significantly inhibits the growth of tumors compared to amrubicin alone in mice bearing LX-1 tumor cells. Amrubicin alone or combined with tegafur and uracil also suppresses tumor growth in human cancer xenograft models^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!